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Objective: The purpose of this study was to determine whether thymectomy
in the newborn has a negative effect on immune function. Methods:
Twenty-five neonates (<30 days) who had thymectomy at congenital heart
repair were prospectively studied to determine immune function. The
percentage of T-cell subtypes including CD3 (all T cells), CD4 (helper T
cells), and CD8 (suppressor T cells) was determined. In six patients,
further testing of CD4 cells was done to determine whether they were newly
formed, recent thymic emigrants (CD4, CD45, and RA1), or older educated
lymphocytes (CD4, CD45, and RO1). Response to the mitogen phytohe-
magglutinin and to tetanus toxoid were determined, as were antibody titers
to tetanus. Samples were drawn before the thymectomy, at approximately 3
months after immunization and at 1 year. Ten age-matched control patients
were tested. At follow-up, parents were asked about infections. Results:
Prethymectomy T-cell subsets were all normal and comparable to controls.
At 12 months, the percent of CD3 was significantly less than in the control
group (48% 6 3% versus 64% 6 2% [mean 6 standard error of the mean];
p < 0.01) as was CD4 (31% 6 2% versus 46% 1 2% [mean 6 standard error
of the mean]; p 5 < 0.01). CD8 did not drop. Surprisingly, the percent of
CD4 that were recent thymic emigrants did not decrease significantly (50%
6 8% versus 60% 6 6% [mean 6 standard error of the mean]; p 5 not
significant). Lymphocyte blastogenesis to phytohemagglutinin and tetanus
toxoid and antibody to tetanus were all normal at 12 months. No patient
required readmission for infection, and there were the expected number of
minor infectious events (median 3; 95% confidence interval 1,4). Conclusion:
Thymectomy in neonates results in a modest but significant decrease in
T-lymphocyte levels, but there is no compromise in immune function.
(J Thorac Cardiovasc Surg 1998;115:1041-6)
In the newborn, thymectomy facilitates cannulationfor cardiopulmonary bypass and exposure for mo-
bilization or reconstructing of the aortic arch. Al-
though thymectomy in children who are younger
than 6 months of age and adults has been shown to
be tolerated without compromise of the immune
system,1, 2 there is very little information on the
impact of neonatal thymectomy. The only published
report specifically addressing this issue suggests
avoiding thymectomy in infants younger than 3
months of age because of evidence of impaired
immunity as tested in later childhood.3 To further
investigate this issue, we have prospectively studied
a group of neonates who underwent thymectomy at
the time of cardiopulmonary bypass in the first
month of life.
Patients and methods
Demographics. Twenty-five neonates (,30 days of age)
who had undergone thymectomy at an operation for
congenital heart disease were prospectively entered into
the study. The anatomic diagnosis of heart disease present
in the study patients is documented in Table I. Control
values for tests of immune function were determined in 10
age-matched (3 to 12 months of age) patients who had not
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undergone thymectomy. No study or control patient car-
ried the diagnosis of DiGeorge syndrome or asplenia.
Cell sources. Peripheral blood samples were drawn
from study patients before thymectomy, at approximately
3 months of age (after the first immunization), and at 1
year of age. Three milliliter specimens were collected in
sterile tubes containing heparin at the time of routine
blood sampling and processed within 24 hours. Control
patients had a single sample analyzed.
Immune system testing. Studies performed to evaluate
the immune system are summarized in Table II. T-cell
immunophenotyping was performed by staining with flu-
orescein-labeled monoclonal antibodies to lymphocyte
surface antigens CD2, CD3, CD4, and CD8. In addition,
in some patients further testing of CD4 cells was per-
formed to determine whether they were newly formed,
naive lymphocytes of recent thymic origin (CD4, CD45,
and RA1) or older, educated memory lymphocytes (CD4,
CD45, and RO1). CD45 is a glycoprotein surface antigen
having the two isoforms, RA and RO.
In vitro mitogenic response was evaluated by culturing
lymphocytes for 3 days with phytohemagglutinin (PHA;
Difco Labs). The cells were stimulated with three concen-
trations (100 mg/ml, 20 mg/ml, and 4 mg/ml), and results
were expressed as the maximum proliferation. PHA was
pulsed on day 3 and cells were harvested on day 4.
Blastogenesis transformation of T lymphocytes was deter-
mined by tritiated thymidine incorporation and expressed
as counts per minute (cpm) after subtracting background
counts (experiment minus control). The standard in our
laboratory is to report experiment minus control rather
than stimulation index because, unless control blastogen-
esis is consistent, variations of control counts per minute
will have an inappropriate and misleading effect on the
results. Normal values as determined from the Clinical
Immunology Laboratory at Childrens Hospital Los Ange-
les were considered to be greater than 75 3 103 cpm. This
value has been determined by testing the response of a
large number of control individuals.
Antigenic-specific in vitro responses were tested by
stimulating lymphocytes for 6 days in the presence of
tetanus toxoid (Massachusetts Biological Laboratory,
Boston, Mass.). Tetanus toxoid has been shown to have a
very flat dose-response curve so that, in our laboratory,
multiple concentration testing is not performed. Our
standard concentration of tetanus toxoid is 1:1000. Teta-
nus was pulsed on day 6, and cell harvesting took place on
day 7. Normal values were considered to be greater than
3 3 103 cpm (background subtracted). This lower limit
and the lower limit for antibody titer to tetanus toxoid
have been determined by testing the response of a large
number of control individuals in our laboratory at Child-
rens Hospital Los Angeles.
To measure T-cell to B-cell cooperation, antibody titer
to tetanus toxoid was measured. A value of greater than
0.1 IU was considered normal. Antibody levels were
determined by use of an enzyme-linked immunosorbent
assay and standardized by use of a reference antiserum
with a known concentration of antibody quantified in
international units.
Follow-up. Study patients were followed for at least 1
year. Hospital charts were reviewed to determine whether
there had been an admission for infection or whether
infections had been noted at the time of outpatient visits.
At the 3- and 12-month blood testing interval, families
were questioned about history of infection. The incidence
of infection was compared with measures of immune
function to determine whether there was any correlation.
Statistical analysis. The significance of differences be-
tween means in laboratory indices was determined by use
of the Student t test when the data were normally distrib-
uted. Student Equal Variance t test and Aspen Welch
Unequal Variance test were used when appropriate.
When the data were skewed, Wilcoxon rank sum tests or
Mann-Whitney U (for ties) was applied. The Spearman
rank correlation coefficient was used as a measure of
association when one or both variables were skewed.
Skewness and kurtosis was based on the omnibus normal-
ity test statistic.
Results
T-cell subsets. After thymectomy, patients had a
lower proportion of lymphocytes with the surface
antigens CD3 (all T cells), CD4 (helper T cells), and
CD8 (suppressor/cytotoxic T cells). These changes
were most marked at 12 months (Table III).
Comparing prethymectomy values or control val-
ues for CD3, CD4, or CD8 at the 3-month point,
there was no significant difference. However at 1
year after thymectomy, patients showed a signifi-
cantly decreased percentage of CD3 and CD4 T
cells (p , 0.01). CD8 cells were not significantly
reduced. It should be noted that the reduction in
CD3 did not approach the critically low level of
approximately 20%, which has been associated with
a significant increase in clinical infections.
It is of interest that T-cell subset decreases were
more marked for CD4 than for CD8 T cells. To test
whether this reduction in the CD4 subpopulation
was due to decreased production of new T cells, six
patients had determination of the percentage of
Table I. Congenital heart defects in study
Patients
Transposition of the great vessels 13
Total anomalous pulmonary venous connection 5
Truncus arteriosus 1
Aortic stenosis 2
Pulmonary atresia 1
Hypoplastic left heart syndrome 3
Table II. Tests of immune function
Percent of T lymphocytes with immunophenotype CD3, CD4,
CD8, CD4CD45RO1, CD4CD45RA1
Lymphocyte blastogenesis reaction to PHA and tetanus toxoid
Antibody titer to tetanus toxoid
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CD4, CD45, RA1 and CD4, CD45, RO1 cells. As
shown in Table III, the percentage of CD4 lympho-
cytes that were recent thymic emigrants although
slightly less than control was not significantly de-
creased (p 5 0.356). Thus there was no significant
decrease in the production of new CD4 T cells, in
spite of a surgically “complete” thymectomy.
Response to PHA. Lymphocytes from patients
who had undergone thymectomy showed a normal
response to the mitogen PHA. These results (Table
IV) are expressed as counts per minute 3 103.
Response to tetanus toxoid. The patients’ lym-
phocytes were tested for their response to tetanus
toxoid at 3 months, after all infant immunizations.
At 3 months there were three patients who showed
decreased responses (,3 3 103). However, by 1
year, all patients had normal responses. The results
of these analyses are summarized in Table V. A
cumulative frequency distribution plot has been
included in Fig. 1.
Antibody titer to tetanus toxoid. To test for the
normal interaction between T and B lymphocytes,
the antibody response to tetanus toxoid was mea-
sured in the patients at 3 months and 1 year after the
thymectomy. Although the titer of one patient was
low at 3 months, it normalized by 12 months. Results
are noted in Table VI, and a cumulative frequency
distribution plot is shown in Fig. 2.
Clinical course. Through the first year of life,
none of the study patients required hospital admis-
sion because of infection. There were the usual and
expected number of minor infectious illnesses,
which included incidents of conjunctivitis, sinusitis,
otitis, and bronchitis, most of which were treated
with outpatient antibiotics. The median number of
events per patient was three (95% CI 1,4). In
particular, there was not an increased incidence of
“thrush,” generally considered to be the “hallmark”
of T-cell immunodeficiency.
There was no correlation between the number of
infectious incidents and the degree of reduction in T
cells (total), T-cell subsets, or response to PHA and
tetanus.
Discussion
There is a naturally occurring model of thymic
deficiency that occurs in the DiGeorge syndrome.4-6
This is due to developmental anomalies of the third
and fourth pharyngeal pouches and results in hypo-
plasia or aplasia of the thymus and parathyroid
glands. Because the amount of thymic tissue that
develops in the DiGeorge syndrome is variable,
there is a spectrum of clinical immunologic mani-
festations. The degree of immunopathy correlates
with the percentage of T cells. When the T-cell
count drops to 10% to 15% of lymphocytes, there is
usually an increase in infections, particularly candi-
diasis; if T cells reach 5% or less, life-threatening
infections can occur. It should be noted that al-
though there was some decrease in T cells in our
Table III. Percent of lymphocytes by immunophenotype
Surface antigen
Patient population
Thymectomy (%)
Before operation 3 Months 12 Months Control (%)
CD3 65.2 6 2.9 64.8 6 3.5 48.2 6 2.5* 64.4 6 2.1
CD4 47.4 6 2.6 46.6 6 2.6 30.8 6 2.4* 46 6 1.9
CD8 20.3 6 4.2 19.8 6 7.3 15.5 6 1.4 17.5 6 1.4
CD4CD45RA1 49.8 6 7.6 59.7 6 6.4
CD4CD45RO1 22.3 6 4.5 21 6 3.2
All data given as mean 6 SEM.
*p 5 ,0.01.
Table IV. Blastogenesis to mitogen PHA
PHA
concentration
(m/ml)
Thymectomy patients
Before operation 3 Months 12 Months
100 105.6 6 8.4 132.2 6 10.9 140.9 6 8.9
20 94.6 6 11.2 139.3 6 13.5 123.0 6 10.1
Normal value . 75 3 103.
Data given in counts per minute 3 103 mean 6 SEM.
Table V. Blastogenesis to tetanus toxoid
Patients Median 95% CI
p Value
(versus control)
Thymectomy
3 Months 16.0 9, 34 0.3656
12 Months 23.5 7, 33 0.4622
Controls 30.0 10, 42
p Values were calculated using the Mann-Whitney U test; normal $ 3 3 103.
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neonates who had undergone thymectomy, none of
them approached the theoretically critically low
level of 20%.
Although there is still uncertainly about exactly
what point in time thymectomy might alter immune
function, there are a number of studies that have
addressed the issue. In landmark studies reported in
1961, Miller and associates7, 8 showed that thymec-
tomy in neonatal mice led to immunodeficiency,
principally affecting cell-mediated immune re-
sponse. It was subsequently shown that thymectomy
in older children (.6 months of age) and adults has
no effect on immunity.1, 2 It might be speculated that
the difference between rodent and human immune
outcomes after neonatal thymectomy relate to the
relative level of gestational maturity at the time of
birth. Because rodents are less mature when born,
neonatal thymectomy might be expected to have a
greater impact on immune function. In the only
report that has focused on the effect of neonatal
thymectomy in human beings, Brearley and associ-
ates3 concluded that, although the clinical conse-
quences of early thymectomy were unclear, there
was evidence of impaired immunity as measured in
later infancy. In this retrospective study, the authors
documented a decreased number of T cells and
T-cell subsets that were significantly lower than
age-matched controls (as in this study) but did not
approach the critically low value of 20% of lympho-
cytes as T cells. Although previous work by Hisatomi
and associates9 had suggested that cardiopulmonary
bypass (in adults) caused a transient decrease in
T-cell subsets and PHA response lasting approxi-
mately 1 week, there was no such evidence in the
study conducted by Brearley and associates3 for
control patients who had not undergone thymec-
tomy and who had had heart surgery when mea-
sured at the later interval of 9 to 36 months after the
operation. Brearley and associates also found a
marginally diminished response to PHA at the low-
est dilution of 4 mg/ml. In our laboratory, most
control patients respond maximally to a PHA dilu-
tion of 20 mg/ml. Maximal stimulation has not been
seen at lower doses such as 4 mg/ml. In normal
patients, the response to PHA at 4 mg/ml has been
erratic and not predictive of immune function. We
did, in fact, test some of our study and control
patients with the lower concentration of 4 mg/ml and
Fig. 1. This graph of blastogenesis to tetanus toxiod
(cumulative percent versus frequency distribution) shows
no significant difference in cumulative percentiles of fre-
quencies of counts per minute in thymectomy and control
patients at 3 and 12 months.
Fig. 2. This graph of antibody titer to tetanus toxoid
(cumulative persent versus frequency distribution) shows
no significant difference in cumulative percentiles in anti-
body response to tetanus toxoid in patients after thymec-
tomy at the 3- and 12-month follow-up.
Table VI. Tetanus antibody in patients who had
undergone thymectomy
After
thymectomy Median 95% CI
p Value
(3-month vs 12-month)
3 Months 0.31 0.05, 1.00 0.1998
12 Months 0.83 0.27, 4.80
p Values were calculated with the Mann-Whitney U test; normal $ 0.1 I.U.
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found minimal responses in both control and study
patients. Despite the subtle evidence of decreased
immune function and no evidence of an increased
incidence of infections, Brearley and associates3
concluded that thymectomy in pediatric cardiac
surgery should be avoided. They advocated splitting
the thymus vertically so that it could be held back by
pericardial sutures or, if thymectomy was required,
they suggested a partial excision. On the basis of our
study, we do not concur. Removal of the thymus
provides significantly better exposure, and splitting
or partial resection of thymic tissue often results in
a hemorrhagic gland that may be a source of con-
tinued bleeding.
The present study suggests that there must be
tremendous redundancy or reserve built into the
thymus. Despite what was a surgically “complete”
resection of the encapsulated neonatal thymus, in-
cluding the upper poles that extend into the cervical
area, there was a relatively small effect on T cells.
Most surprisingly, in the patients in whom the
number of new thymic emigrants (CD4, CD45, and
RA1) were tested, there was no evidence that
thymectomy led to a decrease in the number of
newly formed, naive T cells. The continued produc-
tion of new T cells suggests that retained portions of
the thymus, however small, are capable of maintain-
ing adequate T-cell production.
The thymus normally undergoes involution, and
by the second decade of life the number of recent
thymic emigrants (CD4, CD45, and RA1) begins to
significantly decrease.l0 The difference in the ap-
pearance of the pediatric versus adult thymus gland
as seen at sternotomy is consistent with this de-
crease. The significance of the diminished capacity
to produce new thymic T cells is not entirely clear,
but it could be speculated that the increased suscep-
tibility of some elderly individuals to new pathogens,
such as new strains of influenza, may be related to
their inability to produce new CD4, CD45, and RA1
cells. Given this possibility it remains to be seen
whether patients who have had neonatal thymec-
tomy will more rapidly lose their ability to produce
new T cells (accelerated thymic involution) and
what the impact on their immunity will be later in
life.
Limitations of the study
Lack of “true” controls. Because surgical exposure
would be significantly compromised without
thymectomy, it was not deemed appropriate to
prospectively randomize neonates undergoing car-
diac repair into thymectomy and no thymectomy
groups. The possibility of leaving a portion of the
thymus gland was considered. However, this was
believed to be undesirable because of bleeding
issues but could have been a second arm to a future
study if “complete” thymectomy had proved delete-
rious to immune function.
Lack of ability to measure retained thymus. Al-
though the entire encapsulated thymus was removed
(including the upper poles extending into the base of
the neck), there is no way to determine how much
thymic tissue remained. On the basis of our ability to
visualize the mediastinal portion of the thymus at
sternotomy, we would speculate that the retained
portion was in the neck although there could be
small detached thymic rests near the phrenic nerves
where extensive dissection is avoided. It is also
possible that there was significant thymic regenera-
tion from small retained “rests” of tissue. However,
our experience with staged reoperation, which was
carried out in a small number of the patients, did not
reveal an anatomically identifiable thymic structure.
Length of follow-up. We have demonstrated no
significant defects in immune function in the present
study. A longer follow-up would provide informa-
tion on the persistence of the trend toward lower
T-cell counts and the natural history of thymic
involution in these patients. It is our intent to
continue the follow-up.
We thank Earl Leonard (MS, Biostatistics) for his help
with statistical analysis of the data.
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Discussion
Dr. Steven R. Gundry (Loma Linda, Calif.). I congrat-
ulate Dr. Wells and his coauthors on a very nicely
designed and presented study about a question that has
worried most congenital heart surgeons since the onset of
congenital heart surgery; that is, what to do with a thymus
in your way and does it have any consequences. As most of
us surgeons know, when something is in our way we
usually throw it away and then worry about the conse-
quences later. It is a delight to find some real science
placed on this quite puzzling question.
In infant pediatric cardiac transplantation, we have
believed that the elimination of the thymus and perhaps
its T cells may have an effect on the early T-cell–mediated
rejection of the new allograft. However, we have been
disappointed in our large series at Loma Linda to find that
T-cell–mediated rejection, despite a total thymectomy in
all of our patients, is the predominant form of rejection.
T-cell-mediated rejection is only slightly less vigorous than
in a corresponding adult cardiac transplantation popula-
tion. So we too have been unable to prove that thymec-
tomy is beneficial for us in transplantation or, for that
matter, negatively affects immune function.
Also, we have been surprised, often times greatly, by
the regrowth of thymic tissue that we have found during
those few occasions when retransplantation is neces-
sary. During your few reoperations on patients, have
you, in fact, rediscovered thymic tissue at the time of
the operation?
I have only two questions. First, was the total thymec-
tomy done by pulling both lobes of the thymus out of the
neck or were the actual superior aspects of these lobes
visualized directly?
Second, you point out in your article that the control
patients did not have cardiac surgery. Perhaps the author
could speculate as to the effect of cardiopulmonary by-
pass, in and of itself, on immune function and T-cell
population apart from removal of the thymus.
Dr. Wells. Your first question concerns regrowth of the
thymus seen at the time of a reoperation. In the moderate
number of patients who have undergone staged proce-
dures, we have not seen a significant amount of thymic
tissue at the time of resternotomy.
Your second question involved the extent of the
thymectomy and particularly the superior aspect of the
thymic lobes as they extend into the cervical area. We
have found that it is easiest to remove the neonatal
thymus if you take all of the encapsulated tissue including
its cervical extensions. By pulling the superior poles
downward, you can usually identify and ligate the small
vessels that enter the gland from the neck. The fact that
we have made an effort to remove all of the encapsulated
tissue may account for the lack of thymus as seen at
reoperation, yet we speculate that there must be residual
small rests of thymus to account for the presence of the
CD4, CD45, and RA1 (recent thymic emigrants) identi-
fied in our patients after thymectomy. These residual
thymic sites would most likely be high in the neck or
laterally along the area of the phrenic nerves, where our
dissection tends to be less aggressive.
Finally, there was a question on the effect of cardiopul-
monary bypass on T-cell populations and immune function.
We have not done these studies; and although I doubt that
there would be an effect, particularly months after the
procedure, it would not be difficult to get these controls.
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